When paired with another CLL-driving oncogene, like has been recently shown by Taylor and colleagues in mouse models combining the E571K XPO1 mutation with c-Myc or Bcl-2 alterations [24], recurrent mutations to this site stimulate a more aggressive disease phenotype. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.